Table 1 Clinical characteristics of head and neck cancer patients
From: M6P/IGF2Rloss of heterozygosity in head and neck cancer associated with poor patient prognosis
Characteristics | Mutated M6P/IGF2R(n = 30) | Non Mutated M6P/IGF2R(n = 26) | Informative Patients (n = 56) | Excluded Patients(n = 83) |
|---|---|---|---|---|
Gender (No.) | Male: 25 (83%) | Male: 23 (89%) | Male: 48 (86%) | Male: 66 (80%) |
p = 0.71; p = 0.42 | Female: 5 (17%) | Female: 3 (11%) | Female: 8 (14%) | Female: 17 (20%) |
Age (Years) | Median: 60.4 | Median: 60.9 | Median: 61 | Median: 60 |
p = 1.0; p = 0.5 | Range: 37–71 | Range: 39 – 74 | Range: 37 – 74 | Range: 30 – 75 |
Race (No.) | White: 25 (83%) | White: 17 (65%) | White: 42 (75%) | White: 52 (63%) |
p = 0.2; p = 0.3 | Black: 5 (17%) | Black: 8 (31%) | Black: 13 (23%) | Black: 30 (36%) |
Native American: 1 (4%) | Native American: 1 (2%) | Native American: 1 (1%) | ||
Smoking History | Yes: 30 (100%) | Yes: 23 (89%) | Yes: 53 (95%) | Yes: 76 (92%) |
p = 0.1; p = 0.5 | No: 0 (0%) | No: 3 (11%) | No: 3 (5%) | No: 7 (8%) |
Baseline Hgb (g/dL) | Median: 14.2 | Median: 14 | Median: 14.2 | Median: 13.5 |
p = 0.8; p = 0.06 | Range: 11.5 – 17 | Range: 9.9 – 16.9 | Range: 9.9 – 17.3 | Range: 10.8 – 25 |
Karnofsky Performance | Median: 90 | Median: 90 | Median: 90 | Median: 90 |
Status p = 0.9; p = 0.2 | Range: 60–100 | Range: 70 – 100 | Range: 60 – 100 | Range: 60 – 100 |
Tumor Resectability | Yes: 18 (60%) | Yes: 14 (53%) | Yes: 32 (57%) | Yes: 49 (59%) |
p = 0.8; p = 0.5 | No: 12 (40%) | No: 12 (47%) | No: 24 (43%) | No: 34 (41%) |
Follow-up (Months) | Median: 29 | Median: 52 | Median: 38.6 | Median: 28.2 |
Range: 2 – 100 | Range: 3–124 | Range: 2 – 125 | Range: 2 – 97 | |
Treatment (No.) | ||||
p = 0.8; p = 0.8 | ||||
RT alone | 17 (57%) | 16 (61%) | 33 (59%) | 46 (55%) |
RT + Chemotherapy | 13 (43%) | 10 (39%) | 23 (41%) | 37 (45%) |
Tumor Stage (No.) | ||||
p = 0.4; p = 0.3 | ||||
T1 | 0 | 0 | 0 | 1 (1%) |
T2 | 3 (10%) | 6 (23%) | 9 (16%) | 6 (8%) |
T3 | 14 (47%) | 11 (42%) | 25 (45%) | 45 (54%) |
T4 | 13 (43%) | 9 (35%) | 22 (39%) | 30 (36%) |
Tx | 0 | 0 | 0 | 1 (1%) |
Nodal Stage (No.) | ||||
p = 0.6; p = 0.2 | ||||
N0 | 9 (30%) | 8 (31%) | 17 (30%) | 24 (29%) |
N1 | 7 (23%) | 3 (12%) | 10 (18%) | 15 (18%) |
N2 | 12 (40%) | 14 (53%) | 26 (46%) | 30 (36%) |
N3 | 2 (7%) | 1 (4%) | 3 (5%) | 14 (17%) |
Overall Staging (No.) | ||||
p = 0.4; p = 0.08 | ||||
II | 0 | 2 (8%) | 2 (4%) | 0 |
III | 11 (37%) | 7 (27%) | 18 (32%) | 24 (29%) |
IVa | 17 (57%) | 16 (61%) | 33 (59%) | 45 (54%) |
IVb | 2 (7%) | 1 (4%) | 3 (5%) | 14 (17%) |
Primary Tumor Site (No.) | ||||
p = 0.1; p = 0.07 | ||||
Base of tongue | 7 (23%) | 10 (38%) | 17 (30%) | 15 (18%) |
Tonsil | 7 (23%) | 4 (16%) | 11 (20%) | 23 (27%) |
Larynx | 9 (30%) | 3 (11%) | 12 (21%) | 11 (13%) |
Hypopharynx | 3 (10) | 6 (23%) | 9 (16%) | 17 (21%) |
Paranasal Sinuses | 0 | 2 (8%) | 2 (4%) | 5 (6%) |
Oral Cavity | 4 (14%) | 1 (4%) | 5 (9%) | 3 (4%) |
Nasopharynx | 0 | 0 | 0 | 8 (10%) |
Unknown | 0 | 0 | 0 | 1 (1%) |